Created in Nancy in 2013 by Marc Derive, Jean-Jacques Garaud and Prof. Sébastien Gibot, the biotechnology company Inotrem is one of the most promising start-ups as confirmed by again its selection for French Tech 120, a support program for nuggets capable of becoming world-class technological leaders. Inotrem is working on the development of an innovative drug to treat septic shock, a life-threatening emergency for which there is no specific treatment and which is thought to be the cause of the death of some 40,000 French people each year.
As this acute inflammatory pathology, of infectious origin, is not unrelated to infection with Sars-Cov2, the start-up has launched, in parallel with its study still ongoing in septic shock, a clinical study in France, in Belgium and the United States, aiming to test the tolerance and potential efficacy signals of its molecule in Covid-19.
–
“National research priority”
The objective being to counter “the runaway immune system which seems to be the cause of a great respiratory distress. Our drug could be active in controlling this runaway, ”explains Jean-Jacques Garaud, Managing Director.
About sixty patients with severe forms of Covid and admitted to intensive care were included in this study conducted in partnership with the Nancy CHRU among others. This study, declared a “national research priority” by the French government ‘s therapeutic trials steering committee, was funded to the tune of € 7.4 million by the BPI (public investment bank). The first results are expected soon.
–
Chronic inflammatory diseases
At the same time, in 2020 the start-up launched a therapeutic program, in the pre-clinical development phase, around two other molecules, this time targeting chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel diseases or even the liver …
Inotrem currently has 18 employees.
–
